FDA Defers Liraglutide Until Fourth Quarter

FDA Defers Liraglutide Until Fourth Quarter: Novo Nordisk, said on Sept. 23, that the formal feedback from the U.S. Food and Drug Administration has been deferred until the fourth quarter for liraglutide, a once-daily treatment for Type 2 diabetes. "Novo Nordisk continues the constructive dialog with the FDA regarding the regulatory process for liraglutide," the company said in a statement. Novo Nordisk submitted a new-drug application for liraglutide to the FDA on May 23, 2008, and submitted the drug for clearance in Japan on July 14, 2008. On July 3, 2009, Novo Nordisk was cleared to market liraglutide in Europe under the brand name Victoza and has launched the medication there.